ArticleEuropean journal of medical research2025
ddPCR-based profiling of plasma EV-miRNA identifies a noninvasive biomarker panel for tuberculosis.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Downregulated Plasma-Derived Extracellular Vesicle MicroRNAs as Novel Biomarkers for Enhanced Tuberculosis Diagnosis.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundTuberculosis (TB) is a top infectious disease killer; underdiagnosis fuels its spread. Thus, finding perspective non-invasive biomarkers for early tuberculosis (TB) is very essential. Extracellular vesicles (EVs) microRNAs (miRNAs) are promising non-invasive biomarkers for tuberculosis (TB) detection.
methodsTo investigate the feasibility of early diagnosis of TB, we examined plasma-derived EV-miRNAs obtained from patients with active TB (n = 25), asymptomatic tuberculosis (aTB) (n = 25), and latent tuberculosis infection (LTBI) (n = 25). Initially, EVs were isolated from plasma samples using ultracentrifugation and were characterized via nanoparticle tracking analysis and immunoblotting for surface markers. Additionally, we characterized miRNA profiles using RNA sequencing to identify TB-specific EV-miRNAs. EV-miRNAs were further validated by droplet digital PCR (ddPCR).
resultsSeven differentially expressed miRNAs among the clinical subgroups (fold change > 2, P < 0.05) showed the most significant TB-specific expression patterns. Among these, three miRNAs exhibited significant differences. Furthermore, hsa-miR-451a was upregulated and two miRNAs (hsa-miR-1908-5p and hsa-miR-1268b) were downregulated. The optimized three miRNAs panel exhibited superior diagnostic accuracy with area under the curve (AUC) values of 0.970 (95% confidence interval [CI] 0.928-1.000) for discriminating active TB from healthy controls (HCs) and 0.971 (95% CI 0.923-1.000) for distinguishing LTBI from HCs. A combination of two miRNAs (hsa-miR-451a and hsa-miR-1268b) exhibited a good capacity to distinguish patients with aTB from HCs, with an AUC of 0.880 (95% CI 0.771-0.989).
conclusionThis multigroup cohort study established a novel EV-miRNAs signature and demonstrated its clinical utility for TB staging and early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.